Fig. 4: Infusion of genetically modified macrophages in a prostate cancer model.

a, Experimental scheme. Mice were injected twice per week with LGP-Macs, Olfr644^−/− Macs or Vmn2r29^−/− Macs (n = 7 mice per group). b, Tumor growth expressed as a percentage of the initial volume. c, Representative FACS plot of GFP⁻ and GFP⁺ tumor-infiltrating macrophages. d,e, Results of FACS analysis to determine the immune infiltrate in mice injected with LGP, OLFR644-KO or VMN2R29-KO, showing: percentages of cells gated on GFP⁺F4/80⁺CD11b⁺ cells (LGP n = 7, VMN2R29-KO n = 8, OLFR644-KO n = 8) (d); and percentages of proliferating CD39⁺ cells gated on CD8⁺ T cells and FoxP3⁺ CD25⁺ T_reg cells gated on CD4⁺ T lymphocytes (LGP n = 7, VMN2R29-KO n = 7, OLFR644-KO n = 8) (e). f, Experimental scheme: mice were contextually injected orthotopically with Pten^−/−Trp53^−/− and with LGP-Macs (n = 4 mice), Olfr644^−/− Macs (n = 5 mice) or Vmn2r29^−/− Macs (n = 4 mice). g, Tumor volumes calculated at sacrifice. h,i, FACS analysis to determine the immune infiltrate in LGP, OLFR644-KO or VMN2R29-KO injected mice; percentages of cells gated on GFP⁺F4/80⁺CD11b⁺ cells (h) and percentages of CD39⁺ cells gated on CD8⁺ T cells and T_reg cells gated on CD4⁺ T lymphocytes (i) are shown. j, Experimental scheme: mice were injected twice per week with LGP-Macs or Olfr644^−/− Macs and with anti-CD8 antibody or isotype control. k,l, Tumor growth expressed as a percentage of the initial volume (k) and tumor volumes at the day of sacrifice (l) (LGP isotype n = 4, LGP anti-CD8 n = 7, OLFR644 isotype n = 8, OLFR644 anti-CD8 n = 8). Statistical analyses were performed using two-tailed unpaired Student’s t-test. Values are presented as the mean ± s.e.m. All replicates represent biological replicates. Schematic in a created using BioRender.com.